Why Amyris Is Giving Up on Biodiesel, For Now
By Kevin Bullis,
Technology Review
| 05. 09. 2012
New data show that its products cost more than $30 a gallon to make.
Amyris, a company that uses synthetic biology to make alternatives to conventional petroleum products, recently decided to wind down its biofuels business and focus on selling higher-value products such as cosmetics. Now it's clear why.
Details about Amyris were disclosed during the company's earnings call last night. They show just how far the company is from making biofuel profitably, and illustrate why the company is getting out of the biofuels business—for now.
Shortly after it was founded, Amyris had set out to make biofuel using genetically modified organisms and simple chemistry to turn sugar into a type of oil that's similar to diesel. It had some success making biodiesel for buses in Brazil. But the chemicals produced by the company's microörganisms can be used for other things as well, such as moisturizers and fragrances, that sell for higher prices.
Last night, the company said the average selling price for all its products is $7.70 per liter, or $29 per gallon, far higher than the price for petroleum-based diesel. (In Brazil, diesel costs about $1 per liter.)
The average price—which...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Teddy Rosenbluth, The New York Times | 02.09.2026
Dr. Mehmet Oz has urged Americans to get vaccinated against measles, one of the strongest endorsements of the vaccine yet from a top health official in the Trump administration, which has repeatedly undermined confidence in vaccine safety.
Dr. Oz, the...
By Alex Polyakov, The Conversation | 02.09.2026
Prospective parents are being marketed genetic tests that claim to predict which IVF embryo will grow into the tallest, smartest or healthiest child.
But these tests cannot deliver what they promise. The benefits are likely minimal, while the risks to...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...